Focal cortical dysplasia: Molecular disturbances and clinicopathological classification (Review)

Monika Siedlecka1, Wiesława Grajkowska2, Ryszard Galus1

  • 1Department of Histology and Embryology, Center for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.

Insights

Focal cortical dysplasia (FCD) causes drug-resistant epilepsy in children. This review explores FCD subtypes, genetic links, and potential treatments, offering new insights into cortical abnormalities and epilepsy mechanisms.

Area of Science:

  • Neurology
  • Neuroscience
  • Pediatric Epilepsy

Background:

  • Focal cortical dysplasia (FCD) is a leading cause of pediatric drug-resistant epilepsy, especially in children under three.
  • Despite decades of research since its initial description, the precise mechanisms underlying FCD-related cortical abnormalities remain unclear.
  • The International League Against Epilepsy (ILAE) has proposed a new classification system for FCD.

Purpose of the Study:

  • To review current knowledge on clinical and histopathological aspects of FCD, incorporating the new ILAE classification.
  • To analyze clinicopathological associations and surgical outcomes across different FCD subtypes, distinguishing isolated FCD from FCD with principal lesions.
  • To summarize genetic findings, potential epileptogenesis mechanisms, and novel factors contributing to drug resistance in FCD.

Main Methods:

  • Literature review of clinical, histopathological, and genetic studies on Focal Cortical Dysplasia.
  • Analysis of the International League Against Epilepsy's new classification system for FCD.
  • Comparative evaluation of FCD subtypes and their association with principal lesions and surgical outcomes.

Main Results:

  • The review synthesizes current understanding of FCD subtypes, highlighting clinicopathological correlations and surgical outcomes.
  • Genetic studies suggest potential mechanisms for cortical dysregulation and drug resistance in FCD.
  • A comparison between FCD type IIB and tuberous sclerosis-associated brain tumors is presented, exploring a potential link.

Conclusions:

  • Understanding FCD subtypes and their underlying mechanisms is crucial for improving epilepsy treatment in pediatric patients.
  • Further research into genetic factors and novel epileptogenic mechanisms may lead to targeted therapies for drug-resistant epilepsy.
  • The hypothesis that FCD type IIB may represent a localized manifestation of tuberous sclerosis warrants further investigation.